Research programme: psychedelic and empathogenic compounds - MindMed/MindShift Compounds
Latest Information Update: 10 Mar 2021
At a glance
- Originator MindShift Compounds
- Class Drug withdrawal therapies; Ergolines; Neuropsychotherapeutics; Phenethylamines; Tryptamines
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Mental disorders; Substance-related disorders
Most Recent Events
- 10 Mar 2021 Research programme: psychedelic and empathogenic compounds - MindMed/MindShift Compounds is available for licensing as of 12 Feb 2021. https://mindmed.co/
- 12 Feb 2021 Early research in Substance-related disorders in Switzerland (unspecified route)
- 12 Feb 2021 Early research in Substance-related disorders in USA (unspecified route)